AMENDMENT

Listing of Claims:

The following listing of claims replaces all previous listings or version thereof:

1. (Currently amended) A method for inducing cytotoxicity in a cancer cell comprising contacting said cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein the CDDO-Me and the chemotherapeutic agent are provided in a combined amount effective to induce cytotoxicity in said cell.

2-3. (Canceled)

4. (Currently amended) The method of claim 1, wherein the CDDO-Me is contacted with said cancer cell prior to contacting said cell with said chemotherapeutic agent.

5. (Currently amended) The method of claim 1, wherein said chemotherapeutic agent is contacted with said cell prior to contacting said cell with the CDDO-Me.

6. (Canceled)

7. (Currently amended) The method of claim **[[**6**]]**1, wherein said cancer cell is a leukemic cell.

8. (Original) The method of claim 7, wherein said leukemic cell is a blood cancer cell, a myeloid leukemia cell, a monocytic leukemia cell, a myelocytic leukemia cell, a promyelocytic leukemia cell, a myeloblastic leukemia cell, a lymphocytic leukemia cell, an acute myelogenous leukemic cell, a chronic myelogenous leukemic cell, a lymphoblastic leukemia cell, a hairy cell leukemia cell.

9. (Currently amended) The method of claim **[[**6**]]**1, wherein said cancer cell is a solid tumor cell.

10. (Original) The method of claim 9, wherein said solid tumor cell is a bladder cancer cell, a breast cancer cell, a lung cancer cell, a colon cancer cell, a prostate cancer cell, a liver cancer cell, a pancreatic cancer cell, a stomach cancer cell, a testicular cancer cell, a brain cancer cell, an ovarian cancer cell, a lymphatic cancer cell, a skin cancer cell, a brain cancer cell, a bone cancer cell, a soft tissue cancer cell.

11. (Currently amended) The method of claim 1, wherein said cancer cell is located in a human subject.

12. (Previously presented) The method of claim 11, wherein said CDDO-Me is administered locally.

13. (Previously presented) The method of claim 12, wherein said CDDO-Me is administered by direct intratumoral injection.

14. (Previously presented) The method of claim 12, wherein said CDDO-Me is administered by injection into tumor vasculature.

15. (Previously presented) The method of claim 11, wherein said CDDO-Me is administered systemically.

16. (Previously presented) The method of claim 15, wherein the CDDO-Me is administered intravenously.

17. (Previously presented) The method of claim 15, wherein the CDDO-Me is administered intra-arterially.

18. (Previously presented) The method of claim 15, wherein the CDDO-Me is administered intra-peritoneally.

19. (Previously presented) The method of claim 15, wherein the CDDO-Me is administered orally.

20. (Previously presented) The method of claim 15, wherein the CDDO-Me is administered during *ex vivo* purging.

21. (Original) The method of claim 1, wherein said chemotherapeutic agent is doxorubicin, decitabine, daunorubicin, dactinomycin, mitoxantrone, cisplatin, procarbazine, mitomycin, carboplatin, bleomycin, etoposide, teniposide, mechlroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, ifosfamide, melphalan, hexamethylmelamine, thiopeta, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, adriamycin, 5-fluorouracil (5FU), camptothecin, actinomycin-D, hydrogen peroxide , nitrosurea, plicomycin, tamoxifen, taxol, transplatinum, vincristin, vinblastin, TRAIL, dolastatin-10, bryostatin, annamycin, mylotarg, sodium phenylacetate, sodium butyrate, methotrexate, a cortocosteroid or tacrolimus.

22. (Original) The method of claim 1, wherein said chemotherapeutic agent is a retinoid.

23. (Currently amended) The method of claim 22, wherein said retinoid is selected from the group ~~comprising~~consisting of all-*trans*-retinoic acid, 9-*cis*-retinoic acid, LG100268, LGD1069, fenretinide, and CD437~~, a RAR-specific retinoic acid and a RXR-specific retinoic acid~~.

24. (Original) The method of claim 23, wherein said RXR-specific retinoic acid is LG100268.

25. (Previously presented) The method of claim 1, wherein said cell is contacted with the CDDO-Me a second time.

26. (Original) The method of claim 1, wherein said cell is contacted with said chemotherapeutic agent a second time.

27. (Previously presented) The method of claim 1, wherein the CDDO-Me and said chemotherapeutic agent are contacted with said cell at the same time.

28. (Withdrawn) The method of claim 11, further comprising tumor resection.

29. (Withdrawn) The method of claim 28, wherein said tumor resection occurs prior to said contacting.

30. (Withdrawn) The method of claim 28, wherein said contacting comprises treating a resected tumor bed with the CDDO-Me and said chemotherapeutic agent.

31. (Withdrawn) The method of claim 28, wherein said tumor resection occurs after said contacting.

32. (Withdrawn) The method of claim 28, wherein said contacting occurs both before and after said tumor resection.

33. (Previously presented) A method of killing a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to kill said tumor cell.

34-35. (Canceled)

36. (Original) The method of claim 33, wherein said chemotherapeutic agent is a retinoid.

37. (Previously presented) A method of inducing apoptosis in a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein said CDDO-Me and said

chemotherapeutic agent are provided in a combined amount effective to induce apoptosis of said tumor cell.

38-39. (Canceled)

40. (Original) The method of claim 37, wherein said chemotherapeutic agent is a retinoid.

41. (Currently amended) A method of inducing differentiation in a tumor cell comprising contacting said tumor cell with a 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO)-Me and a chemotherapeutic agent, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to induce the differentiation of said tumor cell.

42-43. (Canceled)

44. (Original) The method of claim 41, wherein said chemotherapeutic agent is a retinoid.

45. (Currently amended) A method of treating cancer in a human patient comprising administering 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent to said human patient, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to treat said cancer.

46-47. (Canceled)

48. (Original) The method of claim 45, wherein said chemotherapeutic agent is a retinoid.

49. (Previously presented) A method of potentiating the effect of a chemotherapeutic agent on a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and the chemotherapeutic agent.

50-51. (Canceled)

52. (Original) The method of claim 49, wherein said chemotherapeutic agent is a retinoid.

53. (Previously presented) A method of inhibiting growth of a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent wherein the CDDO-Me and the chemotherapeutic agent are provided in a combined amount effective to inhibit growth of said tumor cell.

54-55. (Canceled)

56. (Original) The method of claim 53, wherein said chemotherapeutic agent is a retinoid.

57. (Previously presented) A method of inducing apoptosis in a lymphoid cell that expresses Bcl-2 comprising contacting said lymphoid cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and an immunosupressive agent.

58. (Original) The method of claim 57, wherein the Bcl-2 is endogenous.

59. (Original) The method of claim 57, wherein the Bcl-2 is exogenous.

60. (Original) The method of claim 59, wherein the Bcl-2 is expressed by a expression vector that comprises a nucleic acid that encodes Bcl-2 under the control of a promoter active in the lymphoid cell.

61. (Original) The method of claim 57, wherein the lymphoid cell is a T-cell.

62. (Original) The method of claim 57, wherein the lymphoid cell is a cancer cell.

63. (Original) The method of claim 57, wherein the lymphoid cell is located in a human.

64. (Previously presented) The method of claim 57, where the immunosuppressive agent is a corticosteroid.

65. (Previously presented) The method of claim 57, where the immunosuppressive agent is a tacrolimus.

66. (Original) The method of claim 57, wherein the lymphoid cell is further contacted with a chemotherapeutic agent.

67-79. (Canceled).